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S U M M A R Y
Background: The aim of this study was to determine the role of baseline hepatitis B virus (HBV) forming
covalently closed circular DNA (HBV cccDNA) in liver inﬂammation in patients infected with HBV with
serum alanine aminotransferase (ALT) levels under two times the upper limit of normal (2  ULN).
Methods: After liver biopsy and serum virological and biochemical marker screening, patients diagnosed
with chronic HBV infection with serum ALT levels under 2  ULN and histological liver inﬂammation of
less than grade G2 were prospectively recruited into this study. Recruitment took place between March
2009 and November 2010 at the Center of Infectious Disease, Sichuan University. Patient virological and
biochemical markers, as well as markers of liver inﬂammation, were monitored.
Results: A total of 102 patients were recruited and 68 met the inclusion criteria; the median follow-up
was 4.1 years (range 3.9–5.2 years). During follow-up, 41 patients (60.3%) exhibited signs of
inﬂammation. Baseline HBV cccDNA >1 copy/cell (odds ratio 9.43, p = 0.049) and liver inﬂammation
grade G1 (odds ratio 5.77, p = 0.046) were both independent predictors of liver inﬂammation.
Conclusions: A higher baseline intrahepatic HBV cccDNA level may increase the risk of liver
inﬂammation. Further investigations will be required to validate HBV cccDNA as an intrahepatic
virological marker of patients who require extended outpatient management.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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According to the World Health Organization (WHO), infection
with hepatitis B virus (HBV) continues to be a major health
problem worldwide. In 2015, the WHO reported that two billion
people had been infected with HBV and that 240 million were
chronic carriers of HBV surface antigen (HBsAg). Chronic HBV
infection is associated with the progression of liver diseases and an
increased risk of cirrhosis, liver failure, and hepatocellular
carcinoma.1
Seeger and Mason recently summarized the molecular biology
of HBV infection.2 When HBV enters the cytoplasm of host
hepatocytes, its partially double-stranded, relaxed-circular DNA
genome (rcDNA) is released and transferred into the nucleus,
forming covalently closed circular DNA (HBV cccDNA), which is the
original template for viral replication. One of its transcription* Corresponding author. Tel.: +86 28 8542 3052; fax: +86 28 8542 3052.
E-mail address: htang6198@hotmail.com (H. Tang).
http://dx.doi.org/10.1016/j.ijid.2016.09.022
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).products, the pregenomic RNA (pgRNA), serves as a template for
reverse transcriptional synthesis of progeny viral DNA.3 pgRNA is
packaged, along with viral proteins also transcribed and translated
from cccDNA, eventually developing into mature HBV particles.
The formation of HBV cccDNA is essential to the life cycle of HBV.
HBV cccDNA persists in hepatocyte nuclei and plays an important
role in the maintenance and relapse of HBV infection.4,5 Therefore,
intrahepatic HBV cccDNA is believed to be an important marker of
disease progression and is frequently measured to evaluate the
efﬁcacy of anti-HBV therapy and to estimate treatment end-
points.6–8
In clinical practice, it was found that most patients who
underwent liver biopsy had normal or slightly elevated serum
alanine aminotransferase (ALT) levels and mild histological
inﬂammation, and most were not considered to be suitable for
antiviral treatment, according to the Chinese guidelines for the
treatment of hepatitis B.9 However, liver inﬂammation may be
aggravated once these patients enter the immune clearance
phase. If outpatient management is insufﬁcient, these patients
may develop severe liver function abnormalities without theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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prone to inﬂammation is particularly important.
Intracellular HBV cccDNA levels were recently reported to be
positively correlated with serum ALT levels and the histological
grade of liver inﬂammation in some cross-sectional studies.10,11
Nevertheless, the capacity of the intracellular HBV cccDNA level to
predict the histological grade of liver inﬂammation remains
controversial.12,13 The objective of this prospective study was to
determine the role of baseline intracellular HBV cccDNA in
predicting liver inﬂammation in patients infected with HBV and
with serum ALT levels under two times the upper limit of normal
(2  ULN).
2. Patients and methods
2.1. Study design and patient eligibility
Consecutive patients with chronic HBV infection who under-
went liver biopsy and serum virological and biochemical marker
screening, and who were eligible, were recruited into this
prospective study at the Center of Infectious Disease of the
hospital between March 2009 and November 2010. All recruited
patients were examined by clinicians. The inclusion criteria were
as follows: (1) age between 18 and 65 years; (2) HBsAg was
detected in the serum for at least 6 months; (3) serum ALT levels
were below 2  ULN; (4) the patient consented to liver biopsy and
assessment of serum virological and biochemical markers; and (5)
written informed consent was obtained for treatment and
inclusion in the database. The exclusion criteria were (1) patient
had ever received antiviral therapy against HBV; (2) infection with
hepatitis A, hepatitis C, hepatitis D, hepatitis E, or human
immunodeﬁciency virus; (3) diagnosis of both compensated and
decompensated liver cirrhosis, or hepatocellular carcinoma; (4)
jaundice caused by obstructive or hemolytic diseases; (5)
prolonged prothrombin time induced by blood system diseases;
(6) Wilson’s disease, alcoholic liver disease, or autoimmune
hepatitis; and (7) comorbidities, or an uncontrolled metabolic or
psychiatric condition. The study protocol was developed in
accordance with the ethical guidelines of the Declaration of
Helsinki and was approved by the independent ethics committee
of the hospital.
2.2. Clinical data, laboratory data, and follow-up
The clinical and laboratory characteristics of all patients were
recorded prospectively in a database. These included (1)
biochemical tests reﬂecting hepatocytic damage, including
serum ALT, aspartate aminotransferase (AST), albumin, total
bilirubin, cholinesterase, and creatinine, all assayed by
colorimetric methods (Modular EVO, Roche, Switzerland); (2)
international normalized ratio (INR) for prothrombin time,
assessed according to the manufacturer’s instructions (Sysmex
CA-7000 Systems, Sysmex, Japan); (3) HBV markers, such as HBV
antigens and antibodies, detected using commercially available
enzyme immunoassays (Alisei Quality System, RADIM, Italy);
(4) HBV DNA, quantiﬁed using a ﬂuorescent quantifying
PCR with a lower limit of detection of 103 copies/ml. All of
these tests are certiﬁed by the American College of Pathologists.
The clinical and laboratory databases and compliance of all
patients were monitored every 3 months until November 19,
2014.
2.3. Ampliﬁcation of intrahepatic HBV cccDNA
The ampliﬁcation of intrahepatic HBV cccDNA was performed
according to previously reported methods.14 Brieﬂy, total DNAwas extracted from 10-mm sections of about 80-mm formalin-
ﬁxed and parafﬁn-embedded liver biopsy tissue using a QIAamp
FFPE DNA Mini Kit (Qiagen, Germany) in accordance with the
manufacturer’s instructions. HBV rcDNA and replicative double-
stranded DNA (dsDNA) and single-stranded DNA (ssDNA) were
digested using the plasmid-safe ATP-dependent enzyme (PSAD)
(Epicentre Technologies Corp., Chicago, IL, USA) at 37 8C for
30 min and terminated at 70 8C for 30 min. The reaction mixture
contained 6.8 ml extracted total DNA, 4 U PSAD, 2 mmol/l ATP,
and 2 ml 10 reaction buffer with water to a ﬁnal volume of
10 ml.
Four pairs of primers were designed for the ﬁrst round of rolling
cycle HBV cccDNA ampliﬁcation (RCA). Ten microliters of PSAD-
digested DNA was mixed with primers at a concentration of
10 mmol/l with 1 ml of 10 reaction buffer. The mixture was
denatured at 95 8C for 3 min and then cooled to room temperature
stepwise from 50 8C for 15 s, 30 8C for 15 s, and 20 8C for 10 min.
The solution was then added to 8.5 ml of reaction mixture
containing primers at a concentration of 10 mmol/l each, 0.2 ml
100 bovine serum albumin, 2.5 mmol/l of dNTP, 1 ml of the Phi29
DNA polymerase (New England Biolabs, Ipswich, MA, USA), and
1 ml of reaction buffer. The reaction was carried out at 30 8C for
18 h and terminated at 65 8C for 10 min.
HBV cccDNA was further speciﬁcally ampliﬁed and quantiﬁed
using TaqMan real-time PCR with a pair of cccDNA-selective
primers and a probe targeting the gap region between the two viral
genome direct repeat regions (DR1 and DR2). Brieﬂy, 25 ml of
reaction solution was prepared containing 3 ml of RCA-ampliﬁed
DNA template, 2.5 mmol/l dNTP, 25 mmol/l MgCl2, 2.5 ml of 10
Taq polymerase PCR buffer, 0.2 mmol/l of selective primers and
probe, 0.1 U of Taq polymerase, and 11.3 ml of ddH2O. The reaction
was carried out by real-time PCR (LightCycler 480, Roche, San
Francisco, CA, USA) at 94 8C for 3 min, followed by 40 cycles of
94 8C for 15 s and 58 8C for 45 s.
2.4. Quantitation of intrahepatic HBV cccDNA
Ten-fold serial dilutions (102–109 copies/ml) of the plasmid
pcDNA3.1 (+)-HBV-WT-C containing the entire wild-type HBV
genotype C genome were used to establish standard curves to
quantify HBV cccDNA. The plasmid was constructed and stored at
20 8C in the Center of Infectious Disease of the hospital. To adjust
for cell numbers, a set of primers and a probe for human b-actin
were also included in the real-time PCR process. The primers and
probes used for HBV cccDNA and b-actin are listed in Table 1. Each
sample was run in duplicate on the same plate. Liver biopsy tissues
from HBV-uninfected patients were used as negative controls. The
amount of HBV cccDNA was expressed as the number of copies per
cell, with the estimation of 6.667 pg of DNA/cell; the methods have
been reported previously in the literature.15,16
2.5. Statistical methods
All quantitative data were expressed as the mean  standard
deviation (SD) and were compared using the t-test. The Chi-square
test or Fisher’s exact test was performed to determine differences
in qualitative data. Pearson’s correlation was used to analyze
the correlations between continuous variables, including log
HBsAg, log HBV DNA, and log cccDNA. Spearman’s test was used
to assess the correlation of risk factors with inﬂammation scores.
Logistic regression analysis was used to assess the inﬂuence of
independent prognostic factors on the risk of liver inﬂammation. A
p-value of <0.05 was considered to indicate statistical signiﬁcance.
Data were analyzed using the statistical software Intercooled
Stata version 8.2 for Windows (StataCorp LP, College Station, TX,
USA).
Table 1
Sequences of primers and probes for ampliﬁcation of HBV cccDNA and b-actin
Primers and probes Sequence Location Polarity
Primers and probe for cccDNA ampliﬁcation
ccc-up GGGGCGCACCTCTCTTTA 1523–1540 Sense
ccc-down AGGCACAGCTTGGAGGC 1886–1870 Anti-sense
ccc-probe FAM-TCACCTCTGCCTAATCATCTC-TAMRA 1825–1845
Primers and probe for b-actin ampliﬁcation
b-up ACTGTGCCCATCTACGAGG 557–576 Sense
b-down CAGGCAGCTCGTAGCTCTT 786–803 Anti-sense
b-probe FAM-CGGGAAATCGTGCGTGAC-TAMRA 689–706
HBV, hepatitis B virus; cccDNA, covalently closed circular DNA.
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3.1. Demographic data and baseline characteristics
A total of 110 patients were recruited during the 20 months
between March 2009 and November 2010. These patients were
divided into two groups according to their hepatitis B e antigen
(HBeAg) status. While the sex composition, family history, total
bilirubin, albumin, HBV genotype, rate of histological inﬂamma-
tion G2, and rate of histological ﬁbrosis S2 of the HBeAg-
positive and HBeAg-negative groups did not differ signiﬁcantly,
patient age, ALT, AST, serum HBV DNA, and serum HBsAg levels
differed signiﬁcantly between these two groups (Table 2).
One patient withdrew from the study due to the development
of lung cancer and six patients were lost to follow-up, thus seven
patients (6.36%) were not included in the ﬁnal analysis. One
hundred and two patients were followed-up for a median of
4 years (range 3.9–5.2 years), but 34 of these patients, who had a
baseline histological grade of inﬂammation G2, were not
included in the ﬁnal analysis (Figure 1).
The 68 remaining eligible patients with baseline serum ALT
<2ULN and histological grade of inﬂammation <G2 were divided
into two groups according to the manifestation of liver inﬂamma-
tion during follow-up. Forty-one patients with inﬂammation
during follow-up (serum ALT level above 2  ULN) were assigned
to group A, and 27 patients who did not experience inﬂammation
during the follow-up (serum ALT level below 2  ULN) were
assigned to group B. While age, sex, serum ALT, total bilirubin, and
albumin did not differ signiﬁcantly between these two groups, the
rate of serum HBeAg positivity, serum HBV DNA, serum HBsAg, and
intrahepatic HBV cccDNA levels differed signiﬁcantly between
groups A and B (Table 3).
3.2. Distribution of HBV cccDNA and serum virological markers
All patients tested positive for intrahepatic HBV cccDNA at
baseline (29.76–146.77 copies/cell). When stratifying allTable 2
Baseline characteristics of the 110 study patientsa
Variables All patients (n = 110) HBeAg-posi
Age, years 33.1  7.6 31.4  7.0 
Sex, male/female 74/36 57/28 
Family history, positive/negative 65/45 49/36 
ALT, IU/l 25 (6–78) 36 (6–78) 
AST, IU/l 26 (5–71) 29 (5–71) 
Total bilirubin, mmol/l 12.36 (3.29–38.5) 12.31 (3.29
Albumin, g/l 50.54 (38.9–66.4) 50.31 (42.3–
Serum HBV DNA, log10 copies/ml 6.69  1.94 7.56  1.11 
Serum HBsAg, log10 IU/ml 4.02  0.95 4.35  0.73 
HBV genotype, B/C 68/42 55/30 
Histological inﬂammation G2 32 (29.1%) 23 (27.1%) 
Histological ﬁbrosis S2 22 (20%) 16 (18.8%) 
HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotran
a Data are presented as the mean  standard deviation, median (range), or number (pe110 patients by HBeAg status, it was observed that the mean
HBV cccDNA level in patients who were positive for HBeAg was
signiﬁcantly higher than that of patients negative for HBeAg
(7.32  0.60 vs. 6.06  0.55 log10 copies/106 cells, p < 0.001), as
shown in Figure 2.
Furthermore, Pearson’s correlation analysis indicated that both
serum HBsAg and HBV DNA correlated positively with the
intrahepatic HBV cccDNA level in HBeAg-positive individuals
(Figure 3). Importantly, eight patients tested positive for HBV
cccDNA (0.1–10.67 copies/cell) although their serum HBV DNA
levels were lower than the limit of detection, suggesting that an
undetectable serum HBV DNA level does not indicate the
elimination of intracellular HBV cccDNA.
3.3. Baseline HBV cccDNA and liver inﬂammation
Baseline serum HBV DNA and HBsAg levels were signiﬁcantly
higher in patients who developed inﬂammation than in patients
who did not experience inﬂammation (Table 3). Similarly, the
intrahepatic HBV cccDNA level in patients who developed
inﬂammation was also signiﬁcantly higher than that in patients
who did not develop inﬂammation, indicating a possible correla-
tion between baseline intracellular cccDNA and inﬂammation.
The median intrahepatic HBV cccDNA level of the 68 eligible
patients was 19.66 copies/cell (range 0.1–146.77 copies/cell).
While all patients in group A had >1 copy of HBV cccDNA per cell,
only 12 of 27 patients in group B had >1 copy of HBV cccDNA per
cell. The rate of hepatic inﬂammation was higher in patients with
>1 copy of HBV cccDNA per cell than in those with <1 copy HBV
cccDNA per cell (64.5% vs. 16.7%, p = 0.033).
Moreover, logistic regression analysis indicated that baseline
HBV cccDNA >1 copy/cell (odds ratio 9.43, p = 0.049) and liver
inﬂammation grade G1 (odds ratio 5.77, p = 0.046) were both
independent risk factors for liver inﬂammation, while HBsAg and
HBV DNA were not. In addition, the capacity of intracellular HBV
cccDNA, serum HBsAg, and HBV DNA to predict liver inﬂammation
was assessed, and it was found that the area under the receivertive patients (n = 85) HBeAg-negative patients (n = 25) p-Value
39.0  6.7 <0.001
17/8 0.930
16/9 0.648
25 (8–56) 0.020
18 (6–40) 0.012
–26.21) 12.51 (3.75–38.5) 0.855
59.8) 51.32 (38.9–66.4) 0.352
3.71  0.88 <0.001
2.93  0.77 <0.001
13/12 0.250
9 (36%) 0.387
6 (24%) 0.569
sferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
rcentage).
Table 3
Comparison of baseline characteristics between group A and group Ba,b
Variables Group A
(n = 41)
Group B
(n = 27)
p-Value
Age, years 32.1  5.8 32.2  6.6 0.986
Male 27 (65.9%) 15 (55.6%) 0.274
Serum ALT, IU/l 27 (11–73) 22 (8–69) 0.118
Total bilirubin, mmol/l 11.8 (3.3–23.9) 10.9 (3.8–20.7) 0.596
Albumin, g/l 49.2 (42.5–59.7) 49.8 (38.9–66.4) 0.964
Serum HBeAg-positive 37 (90.2%) 17 (45.9%) 0.008
Serum HBV DNA,
log10 copies/ml
7.18  1.68 6.04  2.17 0.018
Serum HBsAg, log10 IU/ml 4.33  0.86 3.79  1.10 0.026
Intrahepatic HBV cccDNA,
log10 copies/10
6 cells
7.40  0.58 6.82  0.93 0.003
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus;
HBsAg, hepatitis B surface antigen; cccDNA, covalently closed circular DNA.
a Data are presented as the mean  standard deviation, median (range), or number
(percentage).
b Group A: patients with inﬂammation during follow-up (serum ALT level above
2  ULN); group B: patients who did not experience inﬂammation during the
follow-up (serum ALT level below 2  ULN).
Eligible  pa tien ts wi th ba seline  serum  ALT <2 × ULN  and
accomplished 4 years follow-up  
(N = 102)
Patients with baseline liver  
inflammation  grade  <G2
(n = 68)
Group A
Patients developed  active liver 
inflammatio n during  follow-up
(n =  41)
Group B
Patients  did  not develop  act ive li ver 
inflamma tion  during  follow-up
(n = 27)
Patients with baseline liver  
inflammation grade ≥G2
(n =  34)
Figure 1. Study ﬂowchart.
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95% conﬁdence interval (CI) 0.521–0.784, p = 0.034) was greater
than for serum HBsAg (AUC 0.634, 95% CI 0.499–0.769, p = 0.063)
or serum HBV DNA (AUC 0.600, 95% CI 0.460–0.739, p = 0.166)
(Figure 4).
4. Discussion
In this prospective study it was sought to determine the
capacity of baseline intracellular HBV cccDNA to predict liver
inﬂammation in patients. The results suggest that higher baseline
intrahepatic HBV cccDNA levels may increase the risk of liver
inﬂammation, and further investigations are warranted to validate
HBV cccDNA as an intrahepatic virological marker for the selection
of patients who may require additional outpatient management.
It appears that the lower serum viral load level in the HBeAg-
negative phase is not only caused by repressed intracellular HBV
cccDNA content, but is also inﬂuenced by the replication efﬁciency
of HBV.17 In addition, the detection of lower levels of intracellular
pregenomic RNA also indicates that serum HBV DNA levels are
repressed in HBeAg-negative patients at the transcriptional level
and are inﬂuenced by intracellular HBV cccDNA content and
replication efﬁciency.3 These ﬁndings concur with published data
showing the level of HBV cccDNA in HBeAg-positive patients to be
signiﬁcantly higher than that in HBeAg-negative patients
(p < 0.001).Figure 2. Distribution of intrahepatic HBV cccDNA expression levels in all eligible patie
patients. (B) HBV cccDNA levels in 85 HBeAg-positive patients and 25 HBeAg-negativeIt was found that the serum HBsAg titer and HBV DNA viral load
correlated positively with intrahepatic HBV cccDNA only in the
HBeAg-positive phase, which is consistent with several previous
ﬁndings.18,19 For example, Thompson et al. reported that many
hepatocytes stained positively for HBsAg in HBeAg-positive
patients in whom viral replication was thought to be repressed,
conﬁrming that the association between HBsAg production and
HBV replication breaks down during the HBeAg-negative phase of
HBV infection.18 This phenomenon may be explained by the
production of HBsAg from a source other than the intracellular HBV
cccDNA. In addition, some previous studies have also demonstrat-
ed that the quantity of HBsAg in serum is correlated with the
cccDNA copy number, which required a biopsy.18,20
Furthermore, viral integration into the host genome has
previously been reported to occur during the early stage of
infection in chronic HBV infection.21 Theoretically, a high
preference for integration has been observed in DR1 and DR2
sequences of the HBV genome, and S gene sequences are often
present in the integrated segments.22 HBsAg may be producednts. (A) Distribution of intrahepatic HBV cccDNA expression levels in 110 eligible
 patients.
Figure 3. Correlation between intrahepatic HBV cccDNA and serum virological markers. (A) Serum HBsAg in HBeAg-positive patients. (B) Serum HBsAg in HBeAg-negative
patients. (C) Serum HBV DNA in HBeAg-positive patients. (D) Serum HBV DNA in HBeAg-negative patients.
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viral replication; however, progressive integration might therefore
provide a template for persistent HBsAg production independent
of viral load . Another explanation may involve the preferential
control of the viral replication pathway at a post-transcriptional
level that separates HBV cccDNA and HBsAg. This has been found to
occur in the presence of cytokines such as nuclear factor kappa BFigure 4. Comparison of intrahepatic HBV cccDNA, serum HBV DNA, and HBsAg
levels predicting histological inﬂammation during follow-up using receiver
operating characteristic curve analysis.(NF-kB) in vitro,23 and is consistent with the more profound
immune pressure present in HBeAg-negative chronic HBV infec-
tion.
The correlation between intrahepatic HBV cccDNA and the
histological grade of liver inﬂammation is currently controversial.
Some researchers have observed no statistically signiﬁcant
correlation between HBV cccDNA and the grade of liver
inﬂammation in HBeAg-negative patients,24,25 while other groups
have found that HBeAg-negative patients with more severe liver
inﬂammation have higher levels of intrahepatic HBV cccDNA.26,27
Meanwhile, other reports have indicated that regardless of the
HBeAg status, the HBV cccDNA level is positively correlated with
the histological grade of liver inﬂammation.28 However, these
studies were all cross-sectional, enrolling patients with a wide
range of serum ALT levels. Therefore, their conclusions should be
investigated further in prospective cohort studies. The present
study was novel in that focus was placed only on treatment-naı¨ve
patients with slightly elevated ALT levels and a histological grade
of liver inﬂammation <G2; the results showed that baseline HBV
cccDNA >1 copy/cell and liver inﬂammation grade G1 were both
independent prognostic factors for the risk of liver inﬂammation.
Generally, the host immune system is inclined to clear HBV, but
in doing so causes hepatocellular lesions and liver inﬂammation
during the immune clearance phase. The host immune system is
activated by proteins on the viral surface, which carry epitopes
speciﬁcally targeting the hepatocytes.29 The results of this study
indicate that the HBV DNA viral load, HBsAg and HBeAg titers, and
intrahepatic HBV cccDNA levels are signiﬁcantly higher in HBeAg-
positive patients than in HBeAg-negative patients, and that viral
markers are more strongly correlated with intrahepatic HBV
cccDNA levels in HBeAg-positive patients than in HBeAg-negative
patients. This may be due to the higher levels of viral protein
translation and secretion in patients with higher intracellular HBV
cccDNA, which activate the host immune response. This immune
activation may aggravate inﬂammation, indicating that for
L.-B. Liang et al. / International Journal of Infectious Diseases 52 (2016) 77–8282patients with repeatedly elevated serum ALT levels, the level of
intrahepatic HBV cccDNA should be assessed in addition to
analyzing liver biopsies and grading the inﬂammation histologi-
cally.
However, the conclusions of this study are limited by its scope.
First, although chronic hepatitis B infection with serum ALT levels
below 2  ULN is very frequent in China, few of these patients gave
consent to a liver biopsy. Further studies will be required to verify
the cut-off value of HBV cccDNA that predicts liver inﬂammation.
Second, although the follow-up period was relatively long–a
median of 4.1 years–the patients were not followed up very
regularly, limiting the estimation of the timing of inﬂammation.
Lastly, the histological grade of inﬂammation was evaluated using
the METAVIR system, and further assessments will be required
using the Knodell histology activity index system.
In conclusion, the results of this study suggest that higher
baseline intrahepatic HBV cccDNA levels may increase the risk of
liver inﬂammation, indicating that such patients require additional
outpatient monitoring. Further investigations will be required to
verify HBV cccDNA as a marker of intrahepatic inﬂammation.
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